Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 7/20 | 0.43 |
| ▸ | IDH2 | P48735 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950045 | 0.81 | IDH1 (0.39) | IDH1IDH2ACHEPRMT6LMNA | |
| SCHEMBL21166123 | 0.78 | IDH1 (0.38) | IDH1IDH2PRMT6MAPTKMT2A | |
| SCHEMBL19608565 | 0.78 | IDH1 (0.38) | IDH1IDH2PRMT6MAPTKMT2A | |
| SCHEMBL14487840 | 0.76 | IDH1 (0.39) | IDH1IDH2PRMT6LMNACCR1 | |
| SCHEMBL2766707 | 0.75 | IDH1 (0.38) | IDH1IDH2PRMT6MAPTNPC1 | |
| SCHEMBL17070039 | 0.74 | IDH1 (0.38) | IDH1IDH2PRMT6LMNACASR | |
| SCHEMBL20674846 | 0.74 | PRMT6 (0.31) | IDH1IDH2PRMT6 | |
| SCHEMBL14487777 | 0.72 | KDM4E (0.41) | IDH1IDH2PRMT6LMNACCR1 | |
| SCHEMBL24253420 | 0.72 | IDH1 (0.36) | IDH1IDH2PRMT6LMNAMAPT | |
| SCHEMBL22867118 | 0.72 | ACHE (0.36) | ACHELMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267801-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210171498-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2020151589-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267801-B2 | Therapeutic compounds | NPC1, CCR5, FURIN | IDH1 743/4885IDH2 1156/4885ACHE 2561/4885 |
| US-20210171498-A1 | THERAPEUTIC COMPOUNDS | NPC1, CCR5, FURIN | IDH1 743/4885IDH2 1156/4885ACHE 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.